Michael J. Hallek

The paper identifies tumor-associated surface markers on circulating extracellular vesicles as complementary biomarkers to circulating tumor DNA in high-risk neuroblastoma.

This study shows that systemic MIF is critical for CLL development, regardless of its cellular source, as Mif-deficient hosts resist disease despite adaptive transfer of CLL cells.

The paper introduces TeLEV, a method to track EV proteomes in immune cells, revealing EV-driven immunomodulation through STAT5-dependent mechanisms.

This study shows that reducing CSF1R expression in myeloid cells has limited impact on CLL progression, suggesting that targeting CSF1R alone may not be effective for therapy.

The paper compares macrophage feeder systems to assess their effects on chronic lymphocytic leukemia cells, including phagocytosis, treatment resistance, and transcriptional changes.

This study identifies focal adhesion pathway inhibition as a key mechanism enhancing macrophage phagocytosis and improving anti-CD20 monoclonal antibody therapy in aggressive lymphoma through high-throughput screening and high-content imaging.

This study uses long-read transcriptome sequencing to analyze SF3B1 mutations in CLL and MDS patients, revealing common splicing alterations and their impact on disease prognosis.

This study identifies PCK2 as a biomarker for renal function 12 months after living donor kidney transplantation using proteomic analysis of urinary extracellular vesicles.